{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:50:43Z","timestamp":1770015043615,"version":"3.49.0"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s40265-014-0254-0","type":"journal-article","created":{"date-parts":[[2014,7,17]],"date-time":"2014-07-17T06:24:48Z","timestamp":1405578288000},"page":"1177-1193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["The Role of Atypical Antipsychotics for Treatment of Tourette\u2019s Syndrome: An Overview"],"prefix":"10.1007","volume":"74","author":[{"given":"Cathy L.","family":"Budman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,18]]},"reference":[{"key":"254_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013. pp. 81\u201385.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"254_CR2","first-page":"1","volume":"99","author":"J Leckman","year":"2006","unstructured":"Leckman J, Bloch M, King R, Scahill L. Phenomenology of tics and natural history of tic disorders. Adv Neurol. 2006;99:1\u201316.","journal-title":"Adv Neurol"},{"key":"254_CR3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jpsychores.2008.04.010","volume":"65","author":"C Conelea","year":"2008","unstructured":"Conelea C, Woods D. The influence of contextual factors on tic expression in Tourette\u2019s syndrome: a review. J Psychosom Res. 2008;65:487\u201396.","journal-title":"J Psychosom Res"},{"key":"254_CR4","volume-title":"Tourette\u2019s syndrome & tic disorders: clinical understanding and treatment","author":"S Fahn","year":"1988","unstructured":"Fahn S, Erenberg G. Differential diagnosis of tic phenomena: a neurologic perspective. In: Cohen D, Bruun R, Leckman J, editors. Tourette\u2019s syndrome & tic disorders: clinical understanding and treatment. New York: Wiley; 1988."},{"key":"254_CR5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jpsychores.2009.07.010","volume":"7","author":"M Robertson","year":"2009","unstructured":"Robertson M, Eapen V, Cavanna A. The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res. 2009;7:475\u201383.","journal-title":"J Psychosom Res"},{"key":"254_CR6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jpsychores.2008.03.006","volume":"65","author":"M Robertson","year":"2008","unstructured":"Robertson M. The prevalence and epidemiology of Gilles de la Tourette syndrome. Part I: the epidemiological and prevalence studies. J Psychosom Res. 2008;65:461\u201372.","journal-title":"J Psychosom Res"},{"key":"254_CR7","first-page":"581","volume":"210","author":"L Scahill","year":"2009","unstructured":"Scahill L, Bitscko RH, Visser SN, Blumberg SJ, Centers of Disease Control and Prevention. Prevalence of diagnosed Tourette syndrome in persons aged 6\u201317\u00a0years\u2014United States. MMWR Morb Mortal Wkly Rep. 2009;210:581\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"254_CR8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaac.2011.11.004","volume":"51","author":"J Scharf","year":"2012","unstructured":"Scharf J, et al. Prevalence of Tourette syndrome and chronic tics in the population-based avon longitudinal study of parents and children cohort. J Am Acad Child Adolesc Psychiatry. 2012;51:192\u2013201.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"254_CR9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pediatrneurol.2012.05.002","volume":"47","author":"T Knight","year":"2012","unstructured":"Knight T, Steeves T, Day L, Lowerison M, Jette N, Pringsheim T. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatr Neurol. 2012;47:77\u201390.","journal-title":"Pediatr Neurol"},{"key":"254_CR10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/archpedi.161.2.193","volume":"161","author":"H Atladottir","year":"2007","unstructured":"Atladottir H, Parner E, Schendel D, Dalsgaard S, Thomsen P, Thorsen P. Time trends in reported diagnoses of childhood neuropsychiatric disorders: a Danish cohort study. Arch Pediatr Adolesc Med. 2007;161:193\u20138.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"254_CR11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/WNL.42.3.652","volume":"42","author":"T Hyde","year":"1992","unstructured":"Hyde T, Aaronson B, Randolph C, Rickler K, Weinberger D. Relationship of birth weight to the phenotypic expression of Gilles de la Tourette\u2019s syndrome in monozygotic twins. Neurology. 1992;42:652\u20138.","journal-title":"Neurology"},{"key":"254_CR12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/archpsyc.1985.01790310077011","volume":"42","author":"R Price","year":"1985","unstructured":"Price R, Kidd K, Cohen D, Pauls D, Leckman J. A twin study of Tourette syndrome. Arch Gen Psychiatry. 1985;42:815\u201320.","journal-title":"Arch Gen Psychiatry"},{"key":"254_CR13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-3999(02)00586-X","volume":"55","author":"D Pauls","year":"2003","unstructured":"Pauls D. An update on the genetics of Gilles de la Tourette syndrome. J Psychosom Res. 2003;55:7\u201312.","journal-title":"J Psychosom Res"},{"key":"254_CR14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/mp.2012.69","volume":"18","author":"J Scharf","year":"2013","unstructured":"Scharf J, Mathews C, Neale B, Stewart S, Fagerness J, et al. Genome-wide association study of Tourette\u2019s syndrome. Mol Psychiatry. 2013;18:721\u20138.","journal-title":"Mol Psychiatry"},{"key":"254_CR15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.gde.2011.01.007","volume":"21","author":"M State","year":"2011","unstructured":"State M. The genetics of Tourette disorder. Curr Opin Genet Dev. 2011;21:302\u20139.","journal-title":"Curr Opin Genet Dev"},{"key":"254_CR16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/B978-0-12-411546-0.00006-8","volume":"112","author":"P Paschou","year":"2013","unstructured":"Paschou P, Fernandez T, Sharp F, Heiman G, Hoekstra P. Genetic susceptibility and neurotransmitters in Tourette syndrome. Int Rev Neurobiol. 2013;112:155\u201377.","journal-title":"Int Rev Neurobiol"},{"issue":"9","key":"254_CR17","doi-asserted-by":"crossref","first-page":"e1003864","DOI":"10.1371\/journal.pgen.1003864","volume":"2013","author":"LK Davis","year":"2013","unstructured":"Davis LK, Yu D, Keenan CL, Gamazon ER, Konkashbaev AI, Derks EM, Hounie AG. Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet. 2013;2013(9):e1003864.","journal-title":"PLoS Genet"},{"key":"254_CR18","doi-asserted-by":"crossref","unstructured":"Casetellan Balda L, Williams K, Gallezot J, Porgorelov V, Rapanelli M, Crowley M, Anderson G, Loring E, Gorczyca R, Billingslea E, Wasylink S, Panza K, Ercan-Sencicek A, Krusong K, Leventhal B, Ohtsu H, Bloch M, Hughes Z, Krystal J, Mayes L, de Arujo I, Ding Y, State M, Pittenger C. Histidine decarboxylase deficiency causes Tourette syndrome: parallel findings in humans and mice. Neuron 2014; 82(5):1186-7.","DOI":"10.1016\/j.neuron.2014.05.023"},{"key":"254_CR19","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1056\/NEJMoa0907006","volume":"362","author":"A Ercan-Sencicek","year":"2010","unstructured":"Ercan-Sencicek A, Stillman A, Chrosh A, Bilguvar K, O\u2019Roak B, Mason C, Abbott T, Gupta A, King R, Pauls D, Tichfield J, Heiman G, Singer H, Gilbert D, Hoekstra P, Morgan T, Loring E, Yasuno K, Fernandez T, Sanders S, Louvi A, Cho J, Mane S, Colangelo C, Biederer T, Lifton R, Gunel M, State M. l-Histidine decarboxylase and Tourette\u2019s syndrome. N Engl J Med. 2010;362:1901\u20138.","journal-title":"N Engl J Med"},{"key":"254_CR20","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/jmedgenet-2013-101637","volume":"50","author":"I Karagiannidis","year":"2013","unstructured":"Karagiannidis I, Dehning S, Sandor P, Tarnok Z, Rizzo R, Wolanczyk T, Madruga-Garrido M, Hebegrand J, Nothen M, Lekmkuhl G, Garkas L, Nagy P, Syzmanska U, Anastasiou Z, Stathias V, Androutsos C, Tsironi V, Koumoula A, Barta C, Zill P, Mir P, Muller N, Barr C, Paschou P. Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families. J Med Genet. 2013;50:760\u20134.","journal-title":"J Med Genet"},{"key":"254_CR21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00004583-199003000-00010","volume":"29","author":"JF Leckman","year":"1990","unstructured":"Leckman JF, Dolnansky ES, Hardin MT, Clubb M, Walkup JT, Stevenson J, Pauls DL. Perinatal factors in the expression of Tourette\u2019s syndrome: an exploratory study. J Am Acad Child Adolesc Psychiatry. 1990;29:220\u20136.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"254_CR22","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1176\/appi.ajp.163.6.1066","volume":"163","author":"C Matthews","year":"2006","unstructured":"Matthews C, Bimson B, Lowe T, Herrera L, Budman C, Erenberg G, Naarden A, Bruun R, Freimer N, Reus V. Association between maternal smoking and increased symptom severity in Tourette\u2019s syndrome. Am J Psychiatry. 2006;163:1066\u201373.","journal-title":"Am J Psychiatry"},{"key":"254_CR23","first-page":"273","volume":"85","author":"J Walkup","year":"2001","unstructured":"Walkup J. Epigenetic and environmental risk factors in Tourette syndrome. Adv Neurol. 2001;85:273\u20139.","journal-title":"Adv Neurol"},{"key":"254_CR24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1192\/bjp.bp.112.125468","volume":"204","author":"C Matthews","year":"2014","unstructured":"Matthews C, Scharf J, Miller L, Macdonald-Wallis C, Lawlor D, Ben-Shlomo Y. Association between pre-and perinatal exposures and Tourette syndrome or chronic tic disorder in the ALSPAC cohort. Br J Psychiatry. 2014;204:40\u20135.","journal-title":"Br J Psychiatry"},{"key":"254_CR25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ije\/dys064","volume":"42","author":"A Boyd","year":"2013","unstructured":"Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, Molloy L, Ness A, Ring S, Davey Smith G. Cohort Profile: the \u2018children of the 90s\u2019\u2014the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol. 2013;42:111\u201327.","journal-title":"Int J Epidemiol"},{"key":"254_CR26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ije\/dys066","volume":"42","author":"A Fraser","year":"2013","unstructured":"Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, Henderson J, Macleod J, Molloy L, Ness A, Ring S, Nelson S, Lawlor D. Cohort profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J Epidemiol. 2013;42:97\u2013110.","journal-title":"Int J Epidemiol"},{"key":"254_CR27","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.neubiorev.2013.01.007","volume":"37","author":"M Hornig","year":"2013","unstructured":"Hornig M, Lipkin W. Immune-mediated animal models of Tourette syndrome. Neurosci Biobehav Rev. 2013;37:1120\u201338.","journal-title":"Neurosci Biobehav Rev"},{"key":"254_CR28","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/mds.22504","volume":"24","author":"D Martino","year":"2009","unstructured":"Martino D, Dale R, Gilbert D, Giovannoni G, Leckman J. Immunopathogenic mechanisms in Tourette syndrome: a critical review. Mov Disord. 2009;24:1267\u201379.","journal-title":"Mov Disord"},{"key":"254_CR29","doi-asserted-by":"crossref","first-page":"1000113","DOI":"10.4172\/2161-0665.1000113","volume":"2","author":"SE Swedo","year":"2012","unstructured":"Swedo SE, Leckman JF, Rose NR. From research subgroup to clinical syndrome: modifying the PANDAS criteria to describe PANS (pediatric acute-onset neuropsychiatric syndrome). Pediatr Ther. 2012;2:1000113.","journal-title":"Pediatr Ther"},{"issue":"17","key":"254_CR30","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1212\/WNL.0b013e3182181090","volume":"76","author":"F Brilot","year":"2011","unstructured":"Brilot F, Merheb V, Ding A, Murphy T, Dale R. Antibody binding to neuronal surface in Sydenham chorea but not in PANDAS or Tourette syndrome. Neurology. 2011;76(17):1508\u201313.","journal-title":"Neurology"},{"key":"254_CR31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jpsychores.2009.07.004","volume":"76","author":"D Martino","year":"2009","unstructured":"Martino D, Defazio G, Giovannoni G. The PANDAS subgroup of tic disorders and childhood-onset obsessive compulsive disorder. J Psychosom Res. 2009;76:547\u201357.","journal-title":"J Psychosom Res"},{"key":"254_CR32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1542\/peds.2004-2058","volume":"116","author":"L Mell","year":"2005","unstructured":"Mell L, David R, Owens D. Association between streptococcal infection and obsessive compulsive disorder, Tourette\u2019s syndrome and tic disorder. Pediatrics. 2005;116:58\u201360.","journal-title":"Pediatrics"},{"key":"254_CR33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/cap.2010.0043","volume":"20","author":"T Murphy","year":"2010","unstructured":"Murphy T, Kurlan R, Leckman J. The immunobiology of Tourette\u2019s disorder, pediatric autoimmune neuropsychiatric disorders associated with Streptococcus, and related disorders: a way forward. J Child Adolesc Psychopharmacol. 2010;20:317\u201331.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"254_CR34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archpedi.160.1.65","volume":"160","author":"M Bloch","year":"2006","unstructured":"Bloch M, Peterson BS, Scahill L, Otka J, Katsovich L, Zhang H, Leckman JF. Adulthood outcome of tic and obsessive\u2013compulsive symptom severity in children with Tourette syndrome. Arch Pediatr Adolesc Med. 2006;160:65\u20139.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"254_CR35","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1212\/01.WNL.0000086370.10186.7C","volume":"61","author":"E Pappert","year":"2003","unstructured":"Pappert E, Goetz C, Louis E, Blasucci L, Leurgans S. Objective assessments of longitudinal outcome in Gilles de la Tourette\u2019s syndrome. Neurology. 2003;61:936\u201340.","journal-title":"Neurology"},{"key":"254_CR36","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/CHI.0b013e3181b26e9f","volume":"48","author":"M Bloch","year":"2009","unstructured":"Bloch M, Panza K, Landeros-Weisenberger A, Leckman J. Meta-analysis: treatment of attention-deficit\/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009;48:884\u201393.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"254_CR37","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/mds.23199","volume":"25","author":"J Jankovic","year":"2010","unstructured":"Jankovic J, Gelineau-Kattner R, Davidson A. Tourette\u2019s syndrome in adults. Mov Disord. 2010;25:2171\u20135.","journal-title":"Mov Disord"},{"key":"254_CR38","first-page":"23","volume":"27","author":"N Hassan","year":"2012","unstructured":"Hassan N, Cavanna AE. The prognosis of Tourette syndrome: implications for clinical practice. Funct Neurol. 2012;27:23\u20137.","journal-title":"Funct Neurol"},{"key":"254_CR39","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1001\/archpsyc.64.11.1281","volume":"64","author":"B Peterson","year":"2007","unstructured":"Peterson B, Choi H, Hao X, Amat J, Zhu H, Whiteman R, Liu J, Xu D, Bansal R. Morphologic features of the amygdale and hippocampus in children and adults with Tourette syndrome. Arch Gen Psychiatry. 2007;64:1281\u201391.","journal-title":"Arch Gen Psychiatry"},{"key":"254_CR40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pharmthera.2005.05.003","volume":"108","author":"N Swerdlow","year":"2005","unstructured":"Swerdlow N, Sutherland A. Using animal models to develop therapeutics for Tourette syndrome. Pharmacol Ther. 2005;108:281\u201393.","journal-title":"Pharmacol Ther"},{"key":"254_CR41","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/archneur.60.10.1365","volume":"60","author":"J Mink","year":"2003","unstructured":"Mink J. The basal ganglia and involuntary movements: impaired inhibition of competing motor patterns. Arch Neurol. 2003;60:1365\u20138.","journal-title":"Arch Neurol"},{"key":"254_CR42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/WCO.0b013e328344648c","volume":"24","author":"R Bloch","year":"2011","unstructured":"Bloch R, State M, Pittenger C. Recent advances in Tourette syndrome. Curr Opin Neurol. 2011;24:119\u201325.","journal-title":"Curr Opin Neurol"},{"key":"254_CR43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1155\/2013\/481398","volume":"27","author":"A Rothenberger","year":"2013","unstructured":"Rothenberger A, Roessner V. Functional neuroimaging investigations of motor networks in Tourette syndrome. Behav Neurol. 2013;27:47\u201355.","journal-title":"Behav Neurol"},{"key":"254_CR44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev.neuro.29.051605.112851","volume":"31","author":"A Grabiel","year":"2008","unstructured":"Grabiel A. Habits, rituals, and the evaluative brain. Annual Rev Neurosci. 2008;31:359\u201387.","journal-title":"Annual Rev Neurosci"},{"key":"254_CR45","doi-asserted-by":"crossref","first-page":"12387","DOI":"10.1523\/JNEUROSCI.0150-11.2011","volume":"31","author":"R Feiling","year":"2011","unstructured":"Feiling R, Singer H. Neurobiology of Tourette syndrome: current status and need for further investigation. J Neurosci. 2011;31:12387\u2013123951.","journal-title":"J Neurosci"},{"key":"254_CR46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3109\/00048670903559585","volume":"44","author":"F Levy","year":"2010","unstructured":"Levy F. Internalizing versus externalizing comorbidity: Neural circuit hypothesis. Aust N Z J Psychiatry. 2010;44:399\u2013409.","journal-title":"Aust N Z J Psychiatry"},{"key":"254_CR47","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1176\/jnp.6.4.358","volume":"6","author":"M Mega","year":"1994","unstructured":"Mega M, Cummings J. Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci. 1994;6:358\u201370.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"254_CR48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1600-0404.2003.00228.x","volume":"109","author":"V Eapen","year":"2004","unstructured":"Eapen V, Fox-Hiley P, Banerjee S, Robertson M. Clinical features and associated psychopathology in a Tourette syndrome cohort. Act Neurol Scand. 2004;109:255\u201360.","journal-title":"Act Neurol Scand"},{"key":"254_CR49","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.12968\/hmed.2011.72.2.100","volume":"72","author":"M Robertson","year":"2011","unstructured":"Robertson M. Gilles de la Tourette syndrome: the complexities of phenotype and treatment. Br J Hosp Med (Lond). 2011;72:S1\u20137.","journal-title":"Br J Hosp Med (Lond)"},{"key":"254_CR50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1017\/S0021963099005156","volume":"41","author":"A Carter","year":"2000","unstructured":"Carter A, O\u2019Donnell D, Schultz R, Scahill L, Leckman J, Pauls D. Social and emotional adjustment in children affected with Gilles de la Tourette syndrome: associations with ADHD and family functioning. J Child Psychol Psychiatry. 2000;41:215\u201323.","journal-title":"J Child Psychol Psychiatry"},{"key":"254_CR51","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.brat.2005.08.007","volume":"44","author":"T Deckersbach","year":"2006","unstructured":"Deckersbach T, Rausch S, Buhlmann U, Wilhelm S. Habit reversal versus supportive psychotherapy in Tourette\u2019s disorder: a randomized controlled trial and predictors of treatment response. Behav Res Ther. 2006;44:1079\u201390.","journal-title":"Behav Res Ther"},{"key":"254_CR52","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.2010.607","volume":"303","author":"J Piacentini","year":"2010","unstructured":"Piacentini J, Woods D, Scahill L, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA. 2010;303:1929\u201337.","journal-title":"JAMA"},{"key":"254_CR53","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/archgenpsychiatry.2011.1528","volume":"69","author":"S Wilhelm","year":"2012","unstructured":"Wilhelm S, Peterson A, Piacentini J, Woods D, Deckersbach T, Sukhodolsky D, Chang S, Liu H, Dziura J, Walkup J, Scahill L. Randomized trial of behavior therapy for adults with Tourette syndrome. Arch Gen Psychiatry. 2012;69:795\u2013803.","journal-title":"Arch Gen Psychiatry"},{"key":"254_CR54","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.psychres.2013.09.021","volume":"210","author":"J McGuire","year":"2013","unstructured":"McGuire J, Nyirabahizi E, Kircanski K, Piacentini J, Peterson A, Woods D, Wilhelm S, Walkup J, Scahill L. A cluster analysis of tic symptoms in children and adults with Tourette syndrome: clinical correlates and treatment outcomes. Psychiatry Res. 2013;210:1198\u2013204.","journal-title":"Psychiatry Res"},{"key":"254_CR55","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/mds.25488","volume":"28","author":"L Scahill","year":"2013","unstructured":"Scahill L, Woods DW, Himle M, Peterson AL, Wilhelm S, Piacentini J, McNaught K, Walkup J, Mink J. Current controversies on the role of behavior therapy in Tourette syndrome. Mov Disord. 2013;28:1179\u201383.","journal-title":"Mov Disord"},{"key":"254_CR56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2012.05.043","volume":"68","author":"V Roessner","year":"2013","unstructured":"Roessner V, Schoenefeld K, Buse J, Bender S, Ehrlich S. Pharmacological treatment of tic disorders and Tourette\u2019s syndrome. Neuropharmacology. 2013;68:143\u20139.","journal-title":"Neuropharmacology"},{"key":"254_CR57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/070674371205700302","volume":"57","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinhurst L, Carroll A, Dion Y, Luscombe S, Steeves T, Sandor P. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry. 2012;57:133\u201343.","journal-title":"Can J Psychiatry"},{"key":"254_CR58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00787-011-0163-7","volume":"20","author":"V Roessner","year":"2011","unstructured":"Roessner V, Plessen K, Rothenberger A, Ludolph A, Rizzo R, Skov L, Strand G, Stern J, Termine C, Hoekstra P. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20:173\u201396.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"254_CR59","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11940-010-0095-4","volume":"12","author":"H Singer","year":"2010","unstructured":"Singer H. Treatment of tics and Tourette syndrome. Curr Treat Options Neurol. 2010;12:539\u201361.","journal-title":"Curr Treat Options Neurol"},{"key":"254_CR60","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.nurx.2006.01.009","volume":"3","author":"L Scahill","year":"2006","unstructured":"Scahill L, Erenberg G, Berlin C, Budman C, Coffey B, Jancovic J, Kiessling L, King R, Kurlan R, Lang A, Mink J, Murphy T, Zinner S, Walkup J. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx. 2006;3:192\u2013206.","journal-title":"NeuroRx"},{"key":"254_CR61","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejpn.2013.01.005","volume":"17","author":"R Rizzo","year":"2013","unstructured":"Rizzo R, Guilisano M, Cali P, Curatolo P. Tourette syndrome and comorbid ADHD: current pharmacologic treatment options. Eur J Paediatr Neurol. 2013;17:421\u20138.","journal-title":"Eur J Paediatr Neurol"},{"key":"254_CR62","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ajp.158.7.1067","volume":"158","author":"L Scahill","year":"2001","unstructured":"Scahill L, Chappell P, Kim Y, Schultz R, Katsovich L, Shepherd E, Arnsten A, Cohen D, Leckman J. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158:1067\u201374.","journal-title":"Am J Psychiatry"},{"key":"254_CR63","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1212\/WNL.58.4.526","volume":"58","author":"Tourette Syndrome Study Group","year":"2002","unstructured":"Tourette Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58:526\u201336.","journal-title":"Neurology"},{"key":"254_CR64","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.neubiorev.2012.09.008","volume":"37","author":"H Weisman","year":"2013","unstructured":"Weisman H, Qureshi I, Leckman J, Scahill L, Bloch M. Systematic review: pharmacological treatment of tic disorders\u2014efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev. 2013;37:1162\u201371.","journal-title":"Neurosci Biobehav Rev"},{"key":"254_CR65","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ejpn.2012.02.004","volume":"16","author":"A Cavanna","year":"2012","unstructured":"Cavanna A, Orth D, Robertson M. Predictors during childhood of future health-related quality of life in adults with Gilles de la Tourette syndrome. Eur J Paediatr Neurol. 2012;16:605\u201312.","journal-title":"Eur J Paediatr Neurol"},{"key":"254_CR66","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10597-011-9465-y","volume":"49","author":"C Conelea","year":"2011","unstructured":"Conelea C, Woods D, Zinner S, Budman C, Murphy T, Scahill L, et al. The impact of Tourette syndrome in adults: results from the Tourette syndrome impact survey. Commun Ment Health J. 2011;49:110\u201320.","journal-title":"Commun Ment Health J"},{"key":"254_CR67","first-page":"457","volume":"31","author":"K Jobson","year":"1995","unstructured":"Jobson K, Potter W. International psychopharmacology algorithm project report: introduction. Psychopharmacol Bull. 1995;31:457\u20139.","journal-title":"Psychopharmacol Bull"},{"key":"254_CR68","doi-asserted-by":"crossref","unstructured":"Murphy T, Lewin A, Storch E, Stock S; the American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. J Am Acad Child Adolesc Psychiatry 2013;52(12):1341\u20131359.","DOI":"10.1016\/j.jaac.2013.09.015"},{"key":"254_CR69","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1155\/2013\/626410","volume":"26","author":"K Waldon","year":"2013","unstructured":"Waldon K, Hill J, Termine C, Balottin U, Cavanna A. Trials of pharmacological interventions for Tourette syndrome: a systematic review. Behav Neurol. 2013;26:265\u201373.","journal-title":"Behav Neurol"},{"key":"254_CR70","first-page":"1243","volume":"38","author":"D Wong","year":"1997","unstructured":"Wong D, Singer H, Brandt J, et al. D-2-like dopamine receptor density in Tourette syndrome measured by PET. J Nucl Med. 1997;38:1243\u20137.","journal-title":"J Nucl Med"},{"key":"254_CR71","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jns.2003.12.006","volume":"219","author":"K Minzer","year":"2004","unstructured":"Minzer K, Lee O, Hong J, Singer H. Increased prefrontal D2 protein in Tourette syndrome: a post-mortem analysis of frontal cortex and striatum. J Neurol Sci. 2004;219:55\u201361.","journal-title":"J Neurol Sci"},{"key":"254_CR72","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jns.2007.01.069","volume":"255","author":"D Yoon","year":"2007","unstructured":"Yoon D, Gause C, Leckman J, Singer H. Frontal dopaminergic abnormality in Tourette syndrome: a postmortem analysis. J Neurol Sci. 2007;255:50\u20136.","journal-title":"J Neurol Sci"},{"key":"254_CR73","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/01.mnm.0000239485.53780.16","volume":"27","author":"C Yeh","year":"2006","unstructured":"Yeh C, Lee C, Chou Y, Chang C, Mar K, Huang W. Evaluating dopamine transporter activity with 99 mTc-TRODAT-1 SPECT in drug na\u00efve Tourette\u2019s adults. Nucl Med Commun. 2006;27:779\u201384.","journal-title":"Nucl Med Commun"},{"key":"254_CR74","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/08830738060210080401","volume":"21","author":"D Gilbert","year":"2006","unstructured":"Gilbert D. Treatment of children and adolescents with tics and Tourette syndrome. J Child Neurol. 2006;21:690\u2013700.","journal-title":"J Child Neurol"},{"key":"254_CR75","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1192\/bjp.114.508.345","volume":"114","author":"A Shapiro","year":"1968","unstructured":"Shapiro A, Shapiro E. Treatment of Gilles de la Tourette\u2019s syndrome with haloperidol. Br J Psychiatry. 1968;114:345\u201350.","journal-title":"Br J Psychiatry"},{"key":"254_CR76","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archpsyc.1989.01810080052006","volume":"46","author":"E Shapiro","year":"1989","unstructured":"Shapiro E, Shapiro A, Fulop G, Hubbard M, Mandell J, Nordlie J, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette\u2019s syndrome. Arch Gen Psychiatry. 1989;46:722\u201330.","journal-title":"Arch Gen Psychiatry"},{"key":"254_CR77","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1176\/ajp.145.5.621","volume":"145","author":"R Bruun","year":"1988","unstructured":"Bruun R. Subtle and under-recognized side effects of neuroleptic treatment in children with Tourette\u2019s disorder. Am J Psychiatry. 1988;145:621\u20134.","journal-title":"Am J Psychiatry"},{"key":"254_CR78","first-page":"578","volume":"119","author":"N Seignot","year":"1961","unstructured":"Seignot N. Un Cas de Maladie de Gilles de la Tourette Gueri par le R.1625. Ann Med Psychol. 1961;119:578\u20139.","journal-title":"Ann Med Psychol"},{"key":"254_CR79","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1176\/ajp.154.8.1057","volume":"154","author":"F Sallee","year":"1997","unstructured":"Sallee F, Nesbitt L, Jackson C, et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette\u2019s disorder. Am J Psychiatry. 1997;154:1057\u201362.","journal-title":"Am J Psychiatry"},{"key":"254_CR80","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1176\/ajp.135.5.585","volume":"135","author":"M Ross","year":"1978","unstructured":"Ross M, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette syndrome. Am J Psychiatry. 1978;135:585\u20137.","journal-title":"Am J Psychiatry"},{"key":"254_CR81","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00004714-199006000-00007","volume":"10","author":"P Sandor","year":"1990","unstructured":"Sandor P, Musisi S, Moldofsky H, Lang A. Tourette syndrome: a follow-up study. J Clin Psychopharmacol. 1990;10:197\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"254_CR82","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0361-9230(83)90192-2","volume":"11","author":"R Borison","year":"1983","unstructured":"Borison R, Ang L, Hamilton W, Diamond B, Davis J. Treatment approaches in Gilles de la Tourette syndrome. Brain Res Bull. 1983;11:205\u20138.","journal-title":"Brain Res Bull"},{"key":"254_CR83","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mds.25692","volume":"29","author":"S Wijemanne","year":"2014","unstructured":"Wijemanne S, Wu L, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014;29:126\u201330.","journal-title":"Mov Disord"},{"issue":"3 Suppl","key":"254_CR84","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1017\/S0317167100038087","volume":"14","author":"J Jankovic","year":"1987","unstructured":"Jankovic J, Rohaidy H. Motor, behavioral and pharmacologic findings in Tourette\u2019s syndrome. Can J Neurol Sci. 1987;14(3 Suppl):541\u20136.","journal-title":"Can J Neurol Sci"},{"key":"254_CR85","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/archneur.1984.04050150049015","volume":"3","author":"C Goetz","year":"1984","unstructured":"Goetz C, Ranner C, Klawans H. Fluphenazine and multifocal tic disorders. Arch Neurol. 1984;3:271\u20132.","journal-title":"Arch Neurol"},{"key":"254_CR86","doi-asserted-by":"crossref","unstructured":"Singer H, Gammon K, Quaskey S. Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci. 1985\u20131986;12(2):71\u20134.","DOI":"10.1159\/000120222"},{"key":"254_CR87","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1176\/ajp.140.9.1183","volume":"140","author":"A Shapiro","year":"1983","unstructured":"Shapiro A, Shapiro E, Eisenkraft G. Treatment of Giles de la Tourette syndrome with pimozide. Am J Psychiatry. 1983;140:1183\u20136.","journal-title":"Am J Psychiatry"},{"key":"254_CR88","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/jnnp.49.7.791","volume":"49","author":"L Regeur","year":"1986","unstructured":"Regeur L, Pakkenberg B, Fog R, Pakkenberg H. Clinical features and long term treatment with pimozide in 65 patients with Gilles de la Tourette\u2019s syndrome. J Neurol Neurosurg Psychiatry. 1986;49:791\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"254_CR89","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1212\/WNL.52.4.874","volume":"52","author":"Tourette Syndrome Study Group","year":"1999","unstructured":"Tourette Syndrome Study Group. Short-term versus longer term pimozide therapy in Tourette\u2019 syndrome: a preliminary study. Neurology. 1999;52:874\u20137.","journal-title":"Neurology"},{"key":"254_CR90","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4088\/JCP.v62n0111","volume":"62","author":"R Bruggeman","year":"2001","unstructured":"Bruggeman R, van der Linden C, Buitelaar C, Jan K, Gericke G, Hawkridge S, Temlett J. Risperidone versus pimozide in Tourette\u2019s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry. 2001;62:50\u20136.","journal-title":"J Clin Psychiatry"},{"key":"254_CR91","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004583-200402000-00017","volume":"43","author":"D Gilbert","year":"2004","unstructured":"Gilbert D, Batterson J, Sethuramamn G, Sallee F. Tic reduction with risperidone versus pimozide in a randomized double-blind cross-over trial. J Am Acad Child Adolesc Psychiatry. 2004;43:206\u201314.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"254_CR92","doi-asserted-by":"crossref","unstructured":"Pringsheim T, Marras C. Pimozide for tics in Tourette\u2019s syndrome. Cochrane Database Syst Rev 2009;(2):CD006996.","DOI":"10.1002\/14651858.CD006996.pub2"},{"key":"254_CR93","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.4088\/JCP.11m07572","volume":"73","author":"H Rogers","year":"2012","unstructured":"Rogers H, Bhattarm A, Zineh I, Gobburu J, Mathis M, Laughren T, Pacanowski M. BYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the US Food and Drug Administration\u2019s new dosing recommendations. J Clin Psychiatry. 2012;73:1187\u201390.","journal-title":"J Clin Psychiatry"},{"key":"254_CR94","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s00115-006-2131-x","volume":"78","author":"K Muller-Vahl","year":"2007","unstructured":"Muller-Vahl K. The benzamides, tiapride, sulpride, and amisulpride in treatment of Tourette\u2019s syndrome. Nervenarz. 2007;78:264\u201371.","journal-title":"Nervenarz"},{"issue":"Suppl 2","key":"254_CR95","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/00004850-199705002-00006","volume":"12","author":"B Scatton","year":"1997","unstructured":"Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, Schoemaker H. Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol. 1997;12(Suppl 2):S29\u201336.","journal-title":"Int Clin Psychopharmacol"},{"key":"254_CR96","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00449911","volume":"237","author":"C Eggers","year":"1988","unstructured":"Eggers C, Rothenberger A, Berghaus U. Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci. 1988;237:223\u20139.","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"254_CR97","unstructured":"Drt\u00edlkov\u00e1 I, Bala\u0161t\u00edkov\u00e1 B, Lemanov\u00e1 H. Clonazepam, clonidine, and tiapride in children with tic disorder. Homeost Health Dis. 1996;37(5):216-216."},{"key":"254_CR98","first-page":"516","volume":"40","author":"H Klepel","year":"1988","unstructured":"Klepel H, Gebelt H, Koch R, Tzenow H. Treatment of extrapyramidal hyperkineses in children with tiapride. Psychiatr Neurol Med Psychol. 1988;40:516\u201322.","journal-title":"Psychiatr Neurol Med Psychol"},{"key":"254_CR99","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.mp.4001040","volume":"7","author":"L Pani","year":"2002","unstructured":"Pani L, Gessa G. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Mol Psychiatry. 2002;7:247\u201353.","journal-title":"Mol Psychiatry"},{"key":"254_CR100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/hup.470080505","volume":"8","author":"M George","year":"1993","unstructured":"George M, Trimble M, Robertson M. Fluvoxamine and sulpiride in comorbid obsessive\u2013compulsive disorder and Gilles de la Tourette syndrome. Hum Psychopharmacol Clin Exp. 1993;8:327\u201334.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"254_CR101","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00002826-199006000-00005","volume":"13","author":"M Robertson","year":"1990","unstructured":"Robertson M, Schniden V, Lees A. Management of Gilles e la Tourette syndrome using sulpiride. Clin Neuropharmacol. 1990;13:229\u201335.","journal-title":"Clin Neuropharmacol"},{"key":"254_CR102","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0929-6646(09)60406-X","volume":"108","author":"C Ho","year":"2009","unstructured":"Ho C, Chen H, Chiu N, Shen E, Lue H. Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med Assoc. 2009;108:788\u201393.","journal-title":"J Formos Med Assoc"},{"key":"254_CR103","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1345\/aph.1D497","volume":"38","author":"K Fountoulakis","year":"2004","unstructured":"Fountoulakis K, Iacovides A, St. Kaprinis G. Successful treatment of Tourette\u2019s disorder with amisulpride. Ann Pharmacother. 2004;38:901.","journal-title":"Ann Pharmacother"},{"key":"254_CR104","first-page":"175","volume":"19","author":"M Trillet","year":"1990","unstructured":"Trillet M, Moreau T, Dalery J, de Villard R, Aimard G. Treatment of Gilles de la Tourette\u2019s disease with amisulpride. Presse Med. 1990;19:175.","journal-title":"Presse Med"},{"key":"254_CR105","unstructured":"Off-label use of atypical antipsychotics: an update, comparative effectiveness review No., 43 prepared by the Southern California Evidence-based Practice Center for the Agency for Healthcare Research and Qualify. 2011. http:\/\/www.effectivehealthcare.ahrq.gov\/offlabelantipsych.cfm ."},{"key":"254_CR106","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.euroneuro.2011.04.001","volume":"21","author":"A Zuddas","year":"2011","unstructured":"Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol. 2011;21:609\u201329.","journal-title":"Eur Neuropsychopharmacol"},{"key":"254_CR107","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejpn.2011.12.001","volume":"16","author":"H Rickards","year":"2012","unstructured":"Rickards H, Cavanna A, Worrall R. Treatment practices in Tourette syndrome: The European perspective. Eur J Paedriatr Neurol. 2012;16:361\u20134.","journal-title":"Eur J Paedriatr Neurol"},{"issue":"5","key":"254_CR108","doi-asserted-by":"crossref","first-page":"w770","DOI":"10.1377\/hlthaff.28.5.w770","volume":"28","author":"S Crystal","year":"2009","unstructured":"Crystal S, Olfson M, Huang C, Pincus H, Gerhard R. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009;28(5):w770\u201381.","journal-title":"Health Aff (Millwood)"},{"key":"254_CR109","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jns.2011.06.032","volume":"310","author":"M Frank","year":"2011","unstructured":"Frank M, Piedad J, Rickards H, Cavanna A. The role of impulse control disorders in Tourette syndrome: an exploratory study. J Neurol Sci. 2011;310:276\u20138.","journal-title":"J Neurol Sci"},{"key":"254_CR110","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.63.6.679","volume":"63","author":"M Olfson","year":"2006","unstructured":"Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotics. Arch Gen Psychiatry. 2006;63:679\u201385.","journal-title":"Arch Gen Psychiatry"},{"key":"254_CR111","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1176\/appi.ps.59.5.507","volume":"59","author":"M Domino","year":"2008","unstructured":"Domino M, Swartz M. Who are the new users of antipsychotic medications? Psychiatr Serv. 2008;59:507\u201310.","journal-title":"Psychiatr Serv"},{"key":"254_CR112","doi-asserted-by":"crossref","unstructured":"Zito J, Safer D, de Jong-van den Berg L, Janhsen K, Fgert J, Gardner J, Glaeske G, Valluri S. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2008;2:26.","DOI":"10.1186\/1753-2000-2-26"},{"issue":"90","key":"254_CR113","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.schres.2006.09.025","volume":"2007","author":"J Bobes","year":"2007","unstructured":"Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, CLAMORS Study Collaborative Group. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophre Res. 2007;2007(90):162\u201373.","journal-title":"Schizophre Res"},{"key":"254_CR114","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.euroneuro.2009.04.008","volume":"19","author":"B Vitiello","year":"2009","unstructured":"Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009;19:629\u201335.","journal-title":"Eur Neuropsychopharmacol"},{"key":"254_CR115","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamapsychiatry.2013.2053","volume":"70","author":"W Bobo","year":"2013","unstructured":"Bobo W, Cooper W, Stein M, Olfson M, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry. 2013;70:1067\u201375.","journal-title":"JAMA Psychiatry"},{"key":"254_CR116","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11940-006-0036-4","volume":"8","author":"M Qasaymeh","year":"2006","unstructured":"Qasaymeh M, Mink J. New treatments for tic disorders. Curr Treat Options Neurol. 2006;8:465\u201373.","journal-title":"Curr Treat Options Neurol"},{"key":"254_CR117","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","volume":"47","author":"C Correll","year":"2008","unstructured":"Correll C. Antipsychotic use in children and adolescents: minimizing adverse effects of maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47:9\u201320.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"254_CR118","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1212\/WNL.45.7.1419","volume":"45","author":"L Shulman","year":"1995","unstructured":"Shulman L, Singer C. Weiner risperidone in Gilles de la Tourette syndrome. Neurology. 1995;45:1419.","journal-title":"Neurology"},{"key":"254_CR119","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(94)90389-1","volume":"34","author":"M Stamenkovic","year":"1994","unstructured":"Stamenkovic M, Aschauer H, Kasper S. Risperidone for Tourette\u2019s syndrome. Lancet. 1994;34:1577\u20138.","journal-title":"Lancet"},{"key":"254_CR120","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/mds.870090617","volume":"9","author":"C Linden Van der","year":"1994","unstructured":"Van der Linden C, Bruggeman R, van Woerkom T. Serotonin-dopamine antagonist and Gilles de la Tourette\u2019s syndrome: an open pilot dose-titration study with risperidone. Mov Disord. 1994;9:687\u20138.","journal-title":"Mov Disord"},{"key":"254_CR121","first-page":"29","volume":"57","author":"R Bruun","year":"1996","unstructured":"Bruun R, Budman C. Risperidone as a treatment for Tourette syndrome. J Clin Psychiatry. 1996;57:29\u201331.","journal-title":"J Clin Psychiatry"},{"key":"254_CR122","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/cap.2005.15.318","volume":"15","author":"B Kim","year":"2005","unstructured":"Kim B, Lee B, Hwang J, Shin M, Cho S. Effectiveness and safety of risperidone for children and adolescents with chronic tic or Tourette\u2019s disorder in Korea. J Child Adolesc Psychopharmacol. 2005;15:318\u201324.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"254_CR123","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/00004583-199509000-00011","volume":"34","author":"P Lombroso","year":"1995","unstructured":"Lombroso P, Scahill L, King R, Lynch K, Chappell P, Peterson B, McDougle D, Leckman J. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry. 1995;34:1147\u201352.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"254_CR124","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004714-200202000-00006","volume":"22","author":"Y Dion","year":"2002","unstructured":"Dion Y, Annable L, Sandor P, Couinard G. Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2002;22:31\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"254_CR125","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00004583-200203000-00013","volume":"41","author":"G Gaffney","year":"2002","unstructured":"Gaffney G, Perry P, Lund B, Bever-Stille K, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette\u2019s disorder. J Am Acad Child Adolesc Psychiatry. 2002;41:330\u20136.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"254_CR126","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","volume":"60","author":"L Scahill","year":"2003","unstructured":"Scahill L, Leckman L, Schultz R, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60:1130\u20135.","journal-title":"Neurology"},{"key":"254_CR127","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00004714-200012000-00025","volume":"20","author":"P Sandor","year":"2000","unstructured":"Sandor P, Stephens R. Risperidone treatment of aggressive behavior in children with Tourette syndrome. J Clin Psychopharmacol. 2000;20:710\u20132.","journal-title":"J Clin Psychopharmacol"},{"key":"254_CR128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","volume":"441","author":"S Jordan","year":"2002","unstructured":"Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar C. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441:137\u201340.","journal-title":"Eur J Pharmacol"},{"key":"254_CR129","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400\u201311.","journal-title":"Neuropsychopharmacology"},{"key":"254_CR130","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/mds.21859","volume":"23","author":"M Ben Djebara","year":"2008","unstructured":"Ben Djebara M, Worbe Y, Schupbach M, Hartmann A. Aripiprazole: a treatment for severe coprolalia in \u201crefractory\u201d Gilles de la Tourette syndrome. Mov Disord. 2008;23:438\u201340.","journal-title":"Mov Disord"},{"key":"254_CR131","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/cap.2007.061","volume":"18","author":"C Budman","year":"2008","unstructured":"Budman C, Coffey B, Shechter R, Schrock M, Wieland N, Spirgel A, Simon E. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol. 2008;18:509\u201315.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"254_CR132","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/0269881111408462","volume":"26","author":"A Cavanna","year":"2012","unstructured":"Cavanna A, Selvini C, Termine C, Luoni C, Eddy C, Rickards H. Tolerability profile of aripiprazole in patients with Tourette syndrome. J Psychopharmacol. 2012;26:891\u20135.","journal-title":"J Psychopharmacol"},{"key":"254_CR133","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1089\/cap.2009.0125","volume":"20","author":"Y Cui","year":"2010","unstructured":"Cui Y, Zheng Y, Yang Y, Liu J, Li J. Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette\u2019s disorder: a pilot study in China. J Child Adolesc Psychopharmacol. 2010;20:291\u20138.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"254_CR134","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hup.798","volume":"21","author":"L Davies","year":"2006","unstructured":"Davies L, Stern J, Agrawal N, Robertson M. A case series of patients with Tourette\u2019s syndrome in the United Kingdom titrated with aripiprazole. Hum Psychopharmacol. 2006;21:447\u201353.","journal-title":"Hum Psychopharmacol"},{"key":"254_CR135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/01.jcp.0000150229.69124.66","volume":"25","author":"A Kastrup","year":"2005","unstructured":"Kastrup A, Schotter W, Plewnia C, Bartels M. Treatment of tics in Tourette syndrome with aripiprazole. J Clin Psychopharmacol. 2005;25:94\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"254_CR136","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/15622970701762544","volume":"10","author":"W Kawohl","year":"2009","unstructured":"Kawohl W, Schneider F, Vernaleken I, Neuner I. Aripiprazole in the pharmacotherapy of Gilles de la Tourette syndrome in adult patients. World J Biol Psychiatry. 2009;10:827\u201331.","journal-title":"World J Biol Psychiatry"},{"key":"254_CR137","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/0897190009358771","volume":"23","author":"K Lewis","year":"2010","unstructured":"Lewis K, Rappa L, Sherwood-Jachimowicz D, Larose-Pierre M. Aripiprazole for the treatment of adolescent Tourette\u2019s syndrome: a case report. J Pharm Pract. 2010;23:239\u201344.","journal-title":"J Pharm Pract"},{"key":"254_CR138","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1089\/cap.2009.0035","volume":"19","author":"G Lyon","year":"2009","unstructured":"Lyon G, Sama S, Jummani R, Hirsch S, Spirgel A, Goldman R, Coffey B. Aripiprazole in children and adolescents with Tourette\u2019s disorder: an open-label safety and tolerability study. J Child Adolesc Psychopharmacol. 2009;19:623\u201333.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"254_CR139","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1089\/cap.2011.0081","volume":"22","author":"G Masi","year":"2012","unstructured":"Masi G, Gagliano A, Siracusano R, Berloffa S, Calarese T, Ilardo G, Pfanner C, Magazu A, Cedro C. Aripiprazole in children with Tourette\u2019s disorder and co-morbid attention deficit\/hyperactivity disorder: a 12-week, open-label, preliminary study. J Child Adolesc Psychopharmacol. 2012;22:120\u20135.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"254_CR140","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1017\/S1461145705005365","volume":"8","author":"T Murphy","year":"2005","unstructured":"Murphy T, Bengston M, Soto O, Edge P, Saji M, Shapira N, Yang M. Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol. 2005;8:489\u201390.","journal-title":"Int J Neuropsychopharmacol"},{"key":"254_CR141","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hup.2235","volume":"27","author":"I Neuner","year":"2012","unstructured":"Neuner I, Nordt C, Schneider F, Kawohl W. Effectiveness of aripiprazole in the treatment of adult Tourette patients up to 56\u00a0months. Hum Psychopharmacol. 2012;27:364\u20139.","journal-title":"Hum Psychopharmacol"},{"key":"254_CR142","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/cap.2007.0064","volume":"18","author":"W Seo","year":"2008","unstructured":"Seo W, Sung H, Sea H, Bai D. Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol. 2008;18:197\u2013205.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"254_CR143","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/JCP.0b013e31825ac2cb","volume":"32","author":"C Wenzel","year":"2012","unstructured":"Wenzel C, Kleimann A, Bokemeyer S, Muller-Vahl K. Aripiprazole for the treatment of Tourette syndrome: a case series of 100 patients. J Clin Psychopharmacol. 2012;32:548\u201350.","journal-title":"J Clin Psychopharmacol"},{"key":"254_CR144","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1089\/cap.2006.16.505","volume":"16","author":"H Yoo","year":"2006","unstructured":"Yoo H, Kim J, Kim C. A pilot study of aripiprazole in children and adolescents with Tourette\u2019s disorder. J Child Adolesc Psychopharmacol. 2006;16:505\u20136.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"254_CR145","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4088\/JCP.12m08189","volume":"74","author":"HK Yoo","year":"2013","unstructured":"Yoo HK, Joung YS, Lee J-S, Song DH, Lee YS, Kim J-W, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette\u2019s disorder. J Clin Psychiatry. 2013;74:772\u201380.","journal-title":"J Clin Psychiatry"},{"key":"254_CR146","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s10072-011-0678-1","volume":"32","author":"M Guilsano","year":"2011","unstructured":"Guilsano M, Cali P, Cavanna A, Eddy C, Rickards H, Rizzo R. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci. 2011;32:1213\u20137.","journal-title":"Neurol Sci"},{"key":"254_CR147","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3565(25)12023-5","volume":"275","author":"T Seeger","year":"1995","unstructured":"Seeger T, Seymour P, Schmidt A, Zorn S, Schulz D, Level L, McLean S, Guanowsky V, Howard H, Lower J, et al. Ziprasidone (CP-88.059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995;275:101\u201313.","journal-title":"J Pharmacol Exp Ther"},{"key":"254_CR148","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","volume":"39","author":"F Sallee","year":"2000","unstructured":"Sallee F, Kurlan R, Goetz C, Singer H, Scahill L, Law G, Dittman VM, Chappell PB. Ziprasidone treatment of children and adolescents with Tourette\u2019s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000;39:292\u20139.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"254_CR149","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/01.chi.0000215347.93902.3e","volume":"45","author":"F Sallee","year":"2006","unstructured":"Sallee F, Miceli J, Tensfeldt T, Robarge L, Wilner K, Patel N. Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:720\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"254_CR150","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00702-004-0153-8","volume":"111","author":"J Blair","year":"2004","unstructured":"Blair J, Taggart B, Martin A. Electrocardiographic safety profile and monitoring guidelines in pediatric psychopharmacology. J Neural Transm. 2004;111:791\u2013815.","journal-title":"J Neural Transm"},{"key":"254_CR151","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/0269881105049042","volume":"19","author":"L Scahill","year":"2005","unstructured":"Scahill L, Blair J, Leckman JF, Martin A. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone. J Psychopharmacol. 2005;19:205.","journal-title":"J Psychopharmacol"},{"key":"254_CR152","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.172.4.366a","volume":"172","author":"B Bhadrinath","year":"1998","unstructured":"Bhadrinath B. Olanzapine in Tourette syndrome. Br J Psychiatry. 1998;172:366.","journal-title":"Br J Psychiatry"},{"key":"254_CR153","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00004583-200002000-00008","volume":"39","author":"Z Bengi Semerci","year":"2000","unstructured":"Bengi Semerci Z. Olanzapine in Tourette\u2019s disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:140.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"254_CR154","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4088\/JCP.v62n0412","volume":"62","author":"C Budman","year":"2001","unstructured":"Budman C, Gayer A, Lesser M, Shi Q, Bruun R. An open-label study of the treatment efficacy of olanzapine for Tourette\u2019s disorder. J Clin Psychiatry. 2001;62:290\u20134.","journal-title":"J Clin Psychiatry"},{"key":"254_CR155","first-page":"165","volume":"21","author":"W Hwang","year":"2012","unstructured":"Hwang W. Olanzapine treatment for tics in an adult woman with severe Tourette syndrome. Act Neurol Taiwan. 2012;21:165\u20138.","journal-title":"Act Neurol Taiwan"},{"key":"254_CR156","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00004583-200002000-00007","volume":"39","author":"M Karam-Hage","year":"2000","unstructured":"Karam-Hage M, Ghaziuddin N. Olanzapine in Tourette\u2019s disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:139.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"254_CR157","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/cap.2007.135","volume":"18","author":"J McCracken","year":"2008","unstructured":"McCracken J, Suddath R, Chang S, Thakur S, Piacentini J. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol. 2008;18:501\u20138.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"254_CR158","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s004150070173","volume":"247","author":"M Onofrj","year":"2000","unstructured":"Onofrj M, Paci C, D\u2019Andreamatteo G, Toma L. Olanzapine in severe Gilles de la Tourette syndrome: a 52\u00a0week double-blind cross-over study vs. low-dose pimozide. J Neurol. 2000;247:443\u20136.","journal-title":"J Neurol"},{"key":"254_CR159","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004850-200015010-00003","volume":"1","author":"M Stamenkovic","year":"2000","unstructured":"Stamenkovic M, Schindler S, Aschauer H, De Zwaan M, Willinger U, Resinger E, Kasper S. Effective open-label treatment of Tourette\u2019s disorder with olanzapine. Int Clin Psychopharmacol. 2000;1:23\u20138.","journal-title":"Int Clin Psychopharmacol"},{"key":"254_CR160","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/1044546041648959","volume":"14","author":"R Stephens","year":"2004","unstructured":"Stephens R, Bassel C, Sandor P. Olanzapine in the treatment of aggression and tics in children with Tourette\u2019s syndrome\u2014a pilot study. J Child Adolesc Psychopharmacol. 2004;14:255\u201366.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"254_CR161","first-page":"206","volume":"105","author":"F Eynde Van den","year":"2005","unstructured":"Van den Eynde F, Naudts K, De Saedeleer S, van Heeringen C, Audenart K. Olanzapine in Gilles de la Tourette syndrome: beyond tics. Acta Neurol Belg. 2005;105:206\u201311.","journal-title":"Acta Neurol Belg"},{"key":"254_CR162","first-page":"150","volume":"40","author":"Z Matur","year":"2003","unstructured":"Matur Z, Ucok A. Quetiapine treatment in a patient with Tourette\u2019s syndrome, obsessive compulsive disorder and drug-induced mania. Isr J Psychiatry Relat Sci. 2003;40:150\u20132.","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"254_CR163","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/104454601750284108","volume":"11","author":"H Parraga","year":"2001","unstructured":"Parraga H, Parraga M, Woodward R, Fenning P. Quetiapine treatment of children with Tourette\u2019s syndrome: report of two cases. J Child Adolesc Psychopharmacol. 2001;11:187\u201391.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"254_CR164","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00787-002-0272-4","volume":"11","author":"J Shaller","year":"2002","unstructured":"Shaller J, Behar D. Quetiapine treatment of an adolescent and child tic disorders. Eur Child Adolesc Psychiatry. 2002;11:196\u20137.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"254_CR165","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00044011-200727020-00005","volume":"27","author":"M Copur","year":"2007","unstructured":"Copur M, Arpaci B, Demir T, Narin H. Clinical effectiveness of quetiapine in children and adolescents with Tourette\u2019s syndrome: a retrospective case-note survey. Clin Drug Investig. 2007;27:123\u201330.","journal-title":"Clin Drug Investig"},{"key":"254_CR166","first-page":"177","volume":"49","author":"M Copur","year":"2011","unstructured":"Copur M, Herg\u00fcner S, Arpaci B. Tolerability of quetiapine in children and adolescents with Tourette\u2019s syndrome. Int J Clin Pharmacol Ther. 2011;49:177\u20138.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"254_CR167","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/104454603322572624","volume":"13","author":"N Mukaddes","year":"2003","unstructured":"Mukaddes N, Abali O. Quetiapine treatment of children and adolescents with Tourette\u2019s disorder. J Child Adolesc Psychopharmacol. 2003;13:295\u20139.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"254_CR168","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.4088\/JCP.v68n0726e","volume":"68","author":"J Jonge De","year":"2007","unstructured":"De Jonge J, Cath D, van Balkom A. Quetiapine in patients with Tourette\u2019s disorder: an open-label, flexible-dose study. J Clin Psychiatry. 2007;68:1148\u201350.","journal-title":"J Clin Psychiatry"},{"key":"254_CR169","doi-asserted-by":"crossref","unstructured":"Deutch A, Bourdelais A, Zahm D. The nucleus accumbens core and shell: accumbal compartments and their functional attributes. In: Kalivas P, Barnes C, editors. Limbic motor circuits and neuropsychiatry (pp 114\u2013153). Boca Raton: CRC Press; 1993. pp. 45\u201389.","DOI":"10.1201\/9780429274411-2"},{"key":"254_CR170","unstructured":"US Food and Drug Administration. FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs. 2009. http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm149533.htm ."},{"key":"254_CR171","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/01.chi.0000163279.39598.44","volume":"44","author":"R Nicolson","year":"2005","unstructured":"Nicolson R, Craven-Thuss B, Smith J, McKinlay B, Castellanos F. A randomized, double-blind, placebo-controlled trial of metoclopramide for treatment of Tourette\u2019s disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:640\u20136.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"254_CR172","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/104454604773840562","volume":"14","author":"M Acosta","year":"2004","unstructured":"Acosta M, Castellanos FX. Use of the \u201cinverse neuroleptic\u201d metoclopramide in Tourette syndrome: an open case series. J Child Adoles Psychopharmacol. 2004;14:123\u20138.","journal-title":"J Child Adoles Psychopharmacol"},{"key":"254_CR173","first-page":"1068","volume":"42","author":"T Bastiampillai","year":"2008","unstructured":"Bastiampillai T, Dhillon R, Mohindra R. Exacerbation of tics secondary to clozapine therapy. Aust N Z J Psychiatry. 2008;42:1068\u201370.","journal-title":"Aust N Z J Psychiatry"},{"key":"254_CR174","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1440-1614.2005.01549.x","volume":"39","author":"M Begum","year":"2005","unstructured":"Begum M. Clozapine-induced stuttering, facial tics and myoclonic seizures: a case report. Aust N Z J Psychiatry. 2005;39:202.","journal-title":"Aust N Z J Psychiatry"},{"key":"254_CR175","first-page":"22","volume":"62","author":"D Allison","year":"2001","unstructured":"Allison D, Casey D. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62:22\u201331.","journal-title":"J Clin Psychiatry"},{"key":"254_CR176","first-page":"832","volume":"36","author":"J Scarff","year":"2011","unstructured":"Scarff J, Casey D. Newer oral atypical antipsychotic agents: a review. Pharm Ther. 2011;36:832\u20138.","journal-title":"Pharm Ther"},{"issue":"2 Suppl 1","key":"254_CR177","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/JCP.0b013e318169d4ce","volume":"28","author":"AJ Cutler","year":"2008","unstructured":"Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S20\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"254_CR178","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/DDDT.S17266","volume":"5","author":"M Gahr","year":"2011","unstructured":"Gahr M, Kolle M, Schonfeldt-Lecuona C, Lepping P, Freudenmann R. Paliperidone extended-release: does it have a place in antipsychotic therapy? Drug Des Dev Ther. 2011;5:125\u201346.","journal-title":"Drug Des Dev Ther"},{"key":"254_CR179","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nyas.12296","volume":"1304","author":"S Bennett","year":"2013","unstructured":"Bennett S, Keller A, Walkup J. The future of tic disorder treatment. Ann N Y Acad Sci. 2013;1304:32\u20139.","journal-title":"Ann N Y Acad Sci"},{"issue":"57","key":"254_CR180","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/070674371205700303","volume":"2012","author":"T Steeves","year":"2012","unstructured":"Steeves T, McKinlay BD, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: behavioral therapy, deep brain stimulation, and transcranial magnetic stimulation. Can J Psychiatry. 2012;2012(57):144\u201351.","journal-title":"Can J Psychiatry"},{"key":"254_CR181","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00787-011-0167-3","volume":"20","author":"C Verdellen","year":"2011","unstructured":"Verdellen C, van de Griendt J, Hartman A, Murphy T. European clinical guidelines for Tourette syndrome and other tic disorders. Part III: Behavioral and psychosocial interventions. Eur Child Adolesc Psychiatry. 2011;20:197\u2013207.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"254_CR182","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.neubiorev.2012.10.014","volume":"37","author":"A Hartmann","year":"2013","unstructured":"Hartmann A, Worbe Y. Pharmacological treatment of Gilles de la Tourette syndrome. Neurosci Biobehav Rev. 2013;37:1157\u201361.","journal-title":"Neurosci Biobehav Rev"},{"key":"254_CR183","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00702-013-0979-z","volume":"120","author":"R Thomas","year":"2013","unstructured":"Thomas R, Cavanna A. The pharmacology of Tourette syndrome. J Neural Transm. 2013;120:689\u201394.","journal-title":"J Neural Transm"},{"key":"254_CR184","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/mds.23894","volume":"26","author":"K Muller-Vahl","year":"2011","unstructured":"Muller-Vahl K, Krueger D. Does Tourette syndrome prevent tardive dyskinesia? Mov Disord. 2011;26:2442\u20133.","journal-title":"Mov Disord"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0254-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0254-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0254-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T21:03:39Z","timestamp":1746306219000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0254-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":184,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["254"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0254-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}